Lucia Seminario Vidal MD PhD

Dermatology•Tampa, FL

Assistant Professor, Co-director of the Cutaneous Lymphoma Clinic, Director of Dermatology Consult Service, Director of Clinical Research

Join to View Full Profile

13330 Usf Laurel DrTampa, FL 33612
Phone+1 813-974-2201
Fax+1 813-974-4325

Education & Training

University of Alabama Medical CenterResidency, Dermatology, 2013 - 2015
Cayetano Heredia UniversityClass of 2004
University of North CarolinaPhD

Certifications & Licensure

FL State Medical License 2016 - 2026
AL State Medical License 2012 - 2015
American Board of Dermatology Dermatology

Clinical Trials

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma Start of enrollment: 2013 May 30
COMPLETED
PHASE3
Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma Start of enrollment: 2014 Nov 12
Completed
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) Start of enrollment: 2015 Dec 01
Completed
Phase 3
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL Start of enrollment: 2017 Jan 01
Terminated
Phase 3
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2017 Mar 28
Completed
Phase 3
Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis Start of enrollment: 2018 Jun 25
Completed
Phase 3
A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Nov 14
Terminated
Phase 2
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 May 31
Completed
Phase 2
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2018 Jul 26
Completed
Phase 3
This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). Start of enrollment: 2019 Jan 31
COMPLETED
PHASE3
Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis Start of enrollment: 2019 Jan 31
Completed
Phase 2
A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) Start of enrollment: 2020 Nov 17
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Francine M Foss, Youn H Kim, H Miles Prince, Oleg E Akilov, Christiane Querfeld
Journal of Clinical Oncology. 2025-04-01
A photoaging smartphone application to promote sun safety behaviors among youth in late childhood and adolescence.
Jaclyn Abraham, Nicole Natarelli, Aleena Boby, Grace Wei, Kerry Hennessy
Pediatric Dermatology. 2024-05-21
16 citations
Cytokines and Epidermal Lipid Abnormalities in Atopic Dermatitis: A Systematic Review.
Parth R Upadhyay, Lucia Seminario-Vidal, Brian Abe, Cyrus Ghobadi, Jonathan T Sims
Cells. 2023-12-08

Lectures

Pearls for Challenging Cases in Skin of Color
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019

Other Languages

Spanish